Acromegaly Completed Phase 3 Trials for Octreotide (DB00104)

Back to Acromegaly

Also known as: Acromegalic / Acromegaly (disorder)

IndicationStatusPhase
DBCOND0000951 (Acromegaly)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00225979
Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyTreatment
NCT04076462
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With AcromegalyTreatment
NCT02685709
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyTreatment
NCT01412424
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyTreatment
NCT01137682
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyTreatment
NCT00616551
Efficacy and Safety of C2L-OCT-01 PR in Acromegalic PatientsTreatment
NCT00600886
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyTreatment
NCT00372697
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyTreatment
NCT00128232
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsTreatment